CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31

CervoMed Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$2.31+0.07 (+3.12%)

Close on Oct 19, 2026

Market cap: $23.66M
P/E (TTM): –
Dividend yield: –

CervoMed Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	4.01	9.74	7.14	0	–	–	–	–	–	–	–	–	0.07	0.37	0.57	0.04
Cost of Revenue	–	–	–	–	–	–	–	–	–	–	–	–	0	0.24	2.31	0.21
Gross Profit	–	–	–	–	–	–	–	–	–	–	–	–	0.07	0.14	-1.74	-0.17
Research & Development	22	19	8.44	1.34	8.50	9.43	6.62	5.75	5.09	7.25	3.88	2.86	0.34	–	0	–
General & Administrative	10	9.17	6.52	2.14	7.45	6.44	4.83	6.17	6.19	11	2.52	4.76	7.33	4.57	6.70	2.17
Operating Expenses	32	28	15	3.48	–	–	–	–	–	–	24	15	13	12	15	7.47
Operating Income	-28	-18	-7.81	-3.48	-25	-16	-12	-19	-11	-18	-6.41	-15	-13	-12	-16	-7.64
Interest Expense	–	–	0	0.00	–	–	–	0.00	0.10	0.04	0.31	0.27	0.13	-0.17	0.03	0.08
Interest & Investment Income	1.34	1.94	0.22	0.06	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	1.33	1.94	5.64	-2.33	–	–	–	–	–	–	0.01	-2.56	9.83	-4.94	-6.21	-0.77
Asset Impairment Charges	–	–	–	–	–	–	–	6.93	0	0	11	6.67	1.94	1.42	1.86	0.65
Gain (Loss) on Sale of Assets	–	–	–	0	-0.05	0	–	–	–	-0.01	0.00	-0.01	–	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	-2.50	0	0.24	–	–	–	–
Pretax Income	–	–	–	-16	-25	-16	-11	-19	-2.42	-18	-6.72	-17	-2.97	–	–	–
Income Tax Expense	0	–	–	0	-0.44	-1.68	0.33	-0.44	-1.06	-0.36	0	-2.82	0	0	–	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	-14	-2.97	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	0.50	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	–	-14	-2.46	-6.85	–	–
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	–	0.01	0.02	–	–
Net Income	-27	-16	-2.17	-5.80	-24	-14	-12	-18	-1.36	-18	-6.72	-14	-2.46	-6.87	-23	-8.41
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	0.17	0.50	0.39	–
Net Income to Common	–	–	–	–	-24	-16	-12	-27	-2.62	-18	-24	-14	-2.64	-7.37	-23	–
EPS (Basic)(per share)	-2.98	-2.02	-0.82	-11.20	-12.38	-0.30	-1.76	-8.21	-3.16	-26.40	-38.40	-150.00	-150.00	-1,224.00	-3,900.00	-2,100.00
EPS (Diluted)(per share)	–	–	–	2,038,891.00	1,946,859.00	53,831,973.00	6,706,509.00	3,242,301.00	-29.11	-26.40	-38.40	-150.00	-150.00	-1,224.00	-3,900.00	-2,100.00
Shares Outstanding (Basic, Weighted)(shares)	9.04	8.07	2.66	0.52	–	–	–	3.24	0.83	0.68	0.17	0.10	–	–	0.01	0.00
Shares Outstanding (Diluted, Weighted)(shares)	9.04	8.07	2.66	0.52	–	–	–	3.24	0.85	0.68	0.17	0.10	0.02	0.01	0.01	0.00
EBITDA	–	–	–	-3.48	-25	-16	–	–	–	–	-6.38	-14	-13	-12	-16	-7.59

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -9407.0%
Net margin: -9160.9%
Return on equity, FY2025: -93.9%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: 71.43
Price to book: 1.03
Dividend yield: –